Get the Stockscreener App
4.15
3.49%
0.14
After Hours:
4.15
Larimar Therapeutics Inc stock is traded at $4.15, with a volume of 2.41M.
It is up +3.49% in the last 24 hours and down -17.82% over the past month.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide technology platform. Its flagship product candidate, nomlabofusp, is a subcutaneously administered recombinant fusion protein designed to deliver frataxin (FXN) to the mitochondria of patients with Friedreich's ataxia (FA), a rare genetic disease characterized by insufficient production of FXN. The company also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
See More
Previous Close:
$4.01
Open:
$4.05
24h Volume:
2.41M
Relative Volume:
0.59
Market Cap:
$431.11M
Revenue:
-
Net Income/Loss:
$-165.67M
P/E Ratio:
-1.88
EPS:
-2.2075
Net Cash Flow:
$-113.29M
1W Performance:
-4.38%
1M Performance:
-17.82%
6M Performance:
+19.60%
1Y Performance:
+97.62%
1-Day Range:
$4.00
$4.28
1-Week Range:
$3.88
$4.37
52-Week Range:
$1.73
$6.42
Larimar Therapeutics Inc Stock (LRMR) Company Profile
Name
Larimar Therapeutics Inc
Sector
Industry
Phone
844-511-9056
Address
THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD, PA
Compare LRMR vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LRMR
Larimar Therapeutics Inc
|
4.15 | 416.57M | 0 | -165.67M | -113.29M | -2.2075 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Larimar Therapeutics Inc Stock (LRMR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-29-25 | Initiated | Truist | Buy |
| Oct-16-24 | Initiated | Oppenheimer | Outperform |
| Oct-03-24 | Initiated | Wedbush | Outperform |
| Oct-02-24 | Initiated | H.C. Wainwright | Buy |
| Sep-04-24 | Initiated | Robert W. Baird | Outperform |
| Apr-03-24 | Initiated | Leerink Partners | Outperform |
| Nov-17-23 | Upgrade | Citigroup | Neutral → Buy |
| Oct-19-22 | Initiated | Guggenheim | Buy |
| Feb-15-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| Feb-10-21 | Initiated | JMP Securities | Mkt Outperform |
| Feb-01-21 | Initiated | William Blair | Outperform |
View All
Larimar Therapeutics Inc Stock (LRMR) Latest News
Larimar Data Support Surrogate Endpoint for Nomlabofusp Approval Path - MyChesCo
MSN Money - MSN
Analysts Offer Insights on Healthcare Companies: Stryker (SYK) and Larimar Therapeutics (LRMR) - The Globe and Mail
Larimar Therapeutics, Inc. $LRMR Shares Acquired by AIGH Capital Management LLC - MarketBeat
LRMR Forecast, Price Target & Analyst Ratings | LARIMAR THERAPEUTICS INC (NASDAQ:LRMR) - ChartMill
Millennium Management (LRMR) reports 3.5% ownership; 3,625,278 shares - Stock Titan
Larimar Therapeutics Publishes Cross-Species Findings - GlobeNewswire
Larimar Therapeutics stock dips after pricing $100M share offering - MSN
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Larimar Therapeutics launches proposed $75 million public offering - MSN
LRMR stock on the move: What sparked the 55% jump in the past month? - MSN
Larimar Therapeutics Inc expected to post a loss of 54 cents a shareEarnings Preview - TradingView
Friedreich's Ataxia Pipeline Enters a Transformative Era with - openPR.com
Friedreich’s Ataxia Pipeline Enters a Transformative Era with 20+ Therapies and Strong Clinical Momentum from Larimar Therapeutics, Minoryx Therapeutics, and Design Therapeutics | DelveInsight - Barchart
Larimar Therapeutics (LRMR) Stock: Pricing Evaluation | Q4 2025: Profit DisappointsNet Margin - Cổng thông tin điện tử tỉnh Tây Ninh
Larimar Therapeutics (LRMR) to Release Earnings on Wednesday - MarketBeat
Larimar Therapeutics (NASDAQ: LRMR) targets director votes and higher authorized share count - Stock Titan
[ARS] Larimar Therapeutics, Inc. SEC Filing - Stock Titan
FDA grants breakthrough status to Larimar’s nomlabofusp - MSN
Larimar Therapeutics Reports Q1 2025 Results and Advances Nomlabofusp Development - MSN
Larimar Therapeutics (NASDAQ: LRMR) asks shareholders to double authorized shares to 215M - Stock Titan
Analysts Set Larimar Therapeutics Price Target at $16.50 - National Today
Investment Review: Is Larimar Therapeutics Inc currently under institutional pressure2026 Breakouts & Breakdowns & Stepwise Swing Trade Plans - baoquankhu1.vn
Can Larimar Therapeutics (LRMR) Stock Maintain Growth | Price at $5.14, Up 0.98%Social Buzz - Cổng thông tin điện tử tỉnh Tây Ninh
Pullback Watch: Is Larimar Therapeutics Inc forming a double bottom2026 Earnings Surprises & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
Pharma News: Is Larimar Therapeutics Inc impacted by rising ratesWeekly Stock Summary & Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
Will Larimar Therapeutics (LRMR) Stock Rise in 2026 | Price at $4.79, Down 0.10%Hot Community Stocks - Xã Thanh Hà
Larimar surges on FDA breakthrough status for lead asset - MSN
LRMR Technical Analysis & Stock Price Forecast - Intellectia AI
LRMR PE Ratio & Valuation, Is LRMR Overvalued - Intellectia AI
Biotech Larimar heads to Miami for back-to-back investor meetings in March - Stock Titan
Q1 Earnings Estimate for LRMR Issued By Lifesci Capital - MarketBeat
LRMR SEC FilingsLarimar Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Larimar reports results, advances Nomlabofusp toward FDA filing - MSN
Earnings Recap: Does Larimar Therapeutics Inc have consistent dividend growthMarket Growth Review & High Conviction Buy Zone Alerts - baoquankhu1.vn
Buyback Watch: Is Larimar Therapeutics Incs growth already priced in2026 Weekly Recap & Daily Entry Point Trade Alerts - baoquankhu1.vn
Trend Report: Is Larimar Therapeutics Inc impacted by rising ratesProfit Target & Weekly Top Gainers Trade List - baoquankhu1.vn
Wedbush raises its price target on Larimar Therapeutics (LRMR) to $13 - MSN
Profit Recap: Will Larimar Therapeutics Inc stock hit new highs in YEAR2026 Earnings & Fast Exit and Entry Trade Guides - baoquankhu1.vn
Wedbush Raises its Price Target on Larimar Therapeutics (LRMR) to $13 - Insider Monkey
Larimar Therapeutics Inc Stock (LRMR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.77%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):